Last $1.20 USD
Change Today +0.01 / 0.84%
Volume 1.1M
ETRM On Other Exchanges
As of 5:20 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

enteromedics inc (ETRM) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/8/14 - $2.66
52 Week Low
09/24/13 - $1.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ENTEROMEDICS INC (ETRM)

enteromedics inc (ETRM) Related Businessweek News

No Related Businessweek News Found

enteromedics inc (ETRM) Details

EnteroMedics Inc., a development stage medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. It develops the Maestro System, which limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. The company is evaluating the Maestro System in human clinical trials in the United States, Australia, Mexico, and Norway. EnteroMedics Inc. has collaboration with Mayo Clinic for the development and testing of products for the treatment of obesity. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.

27 Employees
Last Reported Date: 03/27/14
Founded in 2002

enteromedics inc (ETRM) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $354.0K
Co-Founder and Vice President of Clinical & R...
Total Annual Compensation: $264.3K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $293.2K
Senior Vice President of Research & Advanced ...
Total Annual Compensation: $263.7K
Compensation as of Fiscal Year 2013.

enteromedics inc (ETRM) Key Developments

EnteroMedics Inc. Announces Results from the Company's Recharge Pivotal Trial of Vbloc Vagal Blocking Therapy

EnteroMedics Inc. announced the publication of results from the Company's ReCharge Pivotal Trial of VBLOC Vagal Blocking Therapy delivered via the Maestro(R) System for the treatment of patients with obesity in the September 3, 2014 issue (doi:10.1001/jama.2014.10540) of The Journal of the American Medical Association (JAMA). The ReCharge Pivotal Trial of VBLOC(R) Vagal Blocking Therapy for the treatment of obesity is a prospective double-blind, sham-controlled clinical trial involving 239 randomized patients (233 implanted) enrolled at ten sites in the United States and Australia. The trial tested the effectiveness and safety of VBLOC Therapy utilizing EnteroMedics' Maestro(R) Rechargeable (RC) System. All patients in the trial received an implanted device and were randomized in a 2:1 allocation to VBLOC treatment or sham control groups. VBLOC Therapy-treated patients in the ReCharge Study intention to treat (ITT) group, which included all 239 patients randomized, demonstrated a clinically meaningful excess weight loss (EWL) of 24.4% at 12 months that was statistically significant as compared to the rigorous sham control group. These VBLOC patients also maintained their weight loss with 25% EWL at 18 months and 21% EWL at 24 months. At 12 months, the majority (52.5%) lost 20% or more of their excess weight and nearly one-third of VBLOC Therapy treated patients lost 30% or more. Statistically significant improvements were observed in the VBLOC Therapy treatment group in total cholesterol, LDL, triglycerides, systolic and diastolic blood pressure, heart rate and waist circumference. The implant/revision procedure, device or therapy-related serious adverse event rate among VBLOC Therapy treated patients was 3.7% for the treatment arm, well below the prespecified threshold of 15%.

EnteroMedics Inc. Presents at CRT Capital Group's 2nd Annual Investor Conference, Sep-16-2014

EnteroMedics Inc. Presents at CRT Capital Group's 2nd Annual Investor Conference, Sep-16-2014 . Venue: Delamar Hotel, Greenwich, Connecticut, United States.

EnteroMedics Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

EnteroMedics Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, operating loss was $7,354,000 against $6,071,000 a year ago. Net loss was $7,501,000 or $0.11 per basic and diluted share against $6,323,000 or $0.11 per basic and diluted share a year ago. For the six months, operating loss was $13,912,000 against $12,390,000 a year ago. Net loss was $14,234,000 or $0.21 per basic and diluted share against $12,904,000 or $0.25 per basic and diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ETRM:US $1.20 USD +0.01

ETRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ETRM.
View Industry Companies

Industry Analysis


Industry Average

Valuation ETRM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENTEROMEDICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at